Comment on

• Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling.

  Shulman LP, Bateman LH, Creinin MD, Cullins VE, Doyle LL, Godfrey E, Murphy P, Rodriguez P, Spear SJ, Stewart FH, Thomas MA, Westhoff CL, Worthington S. Shulman LP, et al. Contraception. 2006 May;73(5):440-2. doi: 10.1016/j.contraception.2006.01.007. Epub 2006 Mar 13. Contraception. 2006. PMID: 16627028 No abstract available.
• Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.

  Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Kaunitz AM, et al. Contraception. 2006 Aug;74(2):90-9. doi: 10.1016/j.contraception.2006.03.010. Epub 2006 May 19. Contraception. 2006. PMID: 16860045 Clinical Trial.
• Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.

  Paschall S, Kaunitz AM. Paschall S, et al. Contraception. 2008 Nov;78(5):370-6. doi: 10.1016/j.contraception.2008.07.022. Epub 2008 Sep 18. Contraception. 2008. PMID: 18929733
• The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women.

  Vestergaard P, Rejnmark L, Mosekilde L. Vestergaard P, et al. Contraception. 2008 Dec;78(6):459-64. doi: 10.1016/j.contraception.2008.07.014. Epub 2008 Sep 10. Contraception. 2008. PMID: 19014791
• Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.

  Viola AS, Castro S, Marchi NM, Bahamondes MV, Viola CF, Bahamondes L. Viola AS, et al. Contraception. 2011 Aug;84(2):122-7. doi: 10.1016/j.contraception.2010.11.007. Epub 2010 Dec 24. Contraception. 2011. PMID: 21757052